Last March, a report sent to the Centers for Medicare & Medicaid Services (CMS) revealed that the government had received warnings that the healthcare exchange website did not meet certain key requirements for successful rollout.
Last March, a report sent to the Centers for Medicare & Medicaid Services (CMS) revealed that the government had received warnings that the healthcare exchange website did not meet certain key requirements for successful rollout. While officials confirmed that the report hadn’t previously been released, CMS argued that it had taken appropriate steps to address problems identified in the report.
The Healthcare.gov website failed to pass the following 6 tests:
“As we have said many times now and as has been frequently reported, flags were definitely raised throughout the development of the website, as would be the case for any IT project this complex,” said White House spokesman Eric Schultz. “Those issues, including the ones from 6 months before launch, were in turn taken up by the development team housed at CMS. But nobody anticipated the size and scope of the problems we experienced once the site launched. Since that time, experts have been working night and day to get it functioning—and that is where our focus is, and should be, right now.”
The findings come in wake of other turbulent news, including President Obama’s decision to allow insurers to keep offering individual insurance plans that do not comply with the Affordable Care Act’s coverage standards.
“The focus has shifted to ‘keeping what you have,’” stated a Modern Healthcare article. “Had a well-functioning insurance exchange been in place, it is likely that a large number of those people would have found comparable or even better coverage at more affordable prices.”
Around the Web
Report Warned of HealthCare.gov Flaws Last Spring [Politico]
Up next: Postponing the Individual Mandate [Modern Healthcare]
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More